DNA Molecular Biology Trials 
Conversations in Drug Development Trends
NOVEMBER 12, 2024
For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition. These advanced therapeutics harness the power of molecular biology to improve human health.
Codon
FEBRUARY 13, 2024
1 Yet even after more than two decades of research, media hype, and dozens of clinical trials and biotech start-ups that have come and gone, phage therapy has not scaled. No phage-based therapeutic has reached the latter stages of the clinical trial pipeline (where promising results lead to an expanded trial involving thousands of patients).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Broad Institute
AUGUST 7, 2023
STING is primarily on the lookout for DNA, which can indicate either a foreign invader such as a virus or damage to the host tissue or cell. Drugs that activate STING have been developed and tested in clinical trials as cancer immunotherapy drugs that would help stimulate the immune system to destroy tumors. Online August 3, 2023.
Drug Target Review
JUNE 19, 2024
The other powerful benefit is that our cell lines can become any of the cell types of the human body – these cells have within their DNA the capability to become any of the more than 200 human cell types which you might want to manufacture. This provides some regulatory advantages, and of course, significant cost advantages.
Codon
MARCH 12, 2023
Notes on Progress is a monthly roundup of papers and ideas about biology and the future. “The recombinant DNA breakthrough has provided us with a new and powerful approach to the questions that have intrigued and plagued man for centuries. Biology is a Burrito. A new base editor to edit mitochondrial DNA.
The Pharma Data
NOVEMBER 22, 2021
Within close propinquity to AstraZeneca’s new centre is the University of Cambridge’s School of Clinical Medicine, the Medical Research Council Laboratory of Molecular Biology, Cancer Research UK and the Royal Papworth and Addenbrooke’s Hospitals, among others. Of the Company’s workers, further than work simply in R&D.
Dark Matter Blog
JULY 16, 2021
The only subject in school that held my interest was biology. As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. I wanted to use molecular biology to create drugs. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA.
Expert insights. Personalized for you.
72 
Let's personalize your content